stock brokers report is now out: targetn price 52 cents
FY11 Strong growth expected to continue
Despite the recent share price performance, Clover remains considerably undervalued given our dual valuation methodologies. Whilst we do not expect a repeat of Clover?s impressive +56% revenue growth achieved in FY10, we do believe that FY11 still provides Clover with strong growth possibilities, particularly in its core market of Asia. The US market will begin to open up for Clover as its competitor (Martek) which is the dominant player in the US enters a period of patent expirations, thereby reducing its powerful barrier to entry in that lucrative market.
Our new free report contains our latest forecasts and provides an operational update.
For a FREE download of the report go to;
http://www.microequities.com.au
- Forums
- ASX - By Stock
- beautiful set of numbers
stock brokers report is now out: targetn price 52 centsFY11...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CLV (ASX) to my watchlist
(20min delay)
|
|||||
Last
49.0¢ |
Change
-0.005(1.01%) |
Mkt cap ! $60.11M |
Open | High | Low | Value | Volume |
49.0¢ | 49.5¢ | 49.0¢ | $8.983K | 18.23K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 32789 | 49.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
50.0¢ | 44797 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 7695 | 2.000 |
1 | 796 | 1.995 |
1 | 796 | 1.990 |
1 | 796 | 1.985 |
1 | 796 | 1.980 |
Price($) | Vol. | No. |
---|---|---|
2.030 | 7190 | 2 |
2.040 | 2620 | 3 |
2.050 | 16114 | 2 |
2.060 | 2764 | 2 |
2.070 | 3787 | 3 |
Last trade - 15.45pm 15/11/2024 (20 minute delay) ? |
Featured News
CLV (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online